Phospho-Jak1 (Tyr1022/1023) (F11) rabbit mAb

Catalog #: 2411
Select Your Size Price
200 uL (0.5 mg/mL)(2411) $475.00
20 uL (0.5 mg/mL)(2411S) $175.00
From $175.00

Need to make a custom order?

Contact us

Note

20 μL is enough antibody for at least 20 Western blots. 

Product Overview

Description

Jak1 plays an essential role in the IFN-α and IFN-γ response pathways and is tyrosine-phosphorylated upon cellular exposure to these signals. Jak1 oral inhibitors have been used to benefit patients with advanced myelofibrosis, where Jak1 was initially shown to be constitutively active in the peripheral blood cells of these patients. Targeted, small-molecule Jak inhibitors have also been used for treatment of rheumatoid arthritis. In cases of advanced melanoma, acquired resistance to PD-1 blockade drugs is associated with loss-of-functions of mutations in Jak1/2 genes. These mutations block interferon gamma signaling and prevent programmed death ligand 1 (PD-L1) expression in tumor cells.

Product Details

Product Details
Specification Description
Applications Flow Cytometry
Clone Jak1Y10221023-F11
Format Unconjugated
Validated Reactivity Human, Mouse
Cross Reactivity Predicted to work with mouse, rat and other homologues.
Detection Anti-Rabbit IgG
Clonality Monoclonal
Immunogen A synthetic phospho-peptide corresponding to residues surrounding Tyr1022/1023 of human phospho-Jak1
Formulation 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA
Isotype Rabbit IgGk
Preparation Protein A+G
Recommended Usage 1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
Storage -20ºC
Pseudonyms Tyrosine-protein kinase JAK1, Janus kinase 1
Uniprot ID P23458
References Muller M, Briscoe J, Laxton C et al. (1993) Nature. 366: 129-135. Verstovesk S, Kantarjian H, Mesa RA et al. New England Journal of Medicine. 363: 1117-1127. Shin DS, Zaretsky JM, Escuin-Ordinas H et al. (2017) Cancer Discovery. 7:188-201. Boyle DL, Soma K, Hodge J, et al. (2014) Annals of the Rheumatic Diseases. 74: 1311-1316.

Images

Cell Culture Products
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) using Phospho-Jak1 (Tyr1022/1023) antibody Jak1Y10221023-F11 at 0.01µg/mL. Cat. #2411.
Cell Culture Products
Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using Phospho-Jak1 (Tyr1022/1023) antibody Jak1Y10221023-F11 at 0.01µg/mL. Cat. #2411.
Cell Culture Products
Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNα + IL-4 + pervandadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Jak1 (Tyr1022/1023) antibody Jak1Y10221023-F11 at 0.001µg/mL. Cat. #2411.

Associated Products